Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
IPSCIO Report Record List
IPSCIO Record ID: 213673
Lantibiotics, a class of peptide antibiotics that are naturally produced in Gram-positive bacteria and contain the characteristic polycyclic thioether amino acids lanthionine and methyllanthonine. In connection with the research, development, use, importing, manufacture, sale, and offer for sale of drug products involving the direct administration to humans or companies of lantibiotics for the purpose of prevention or treatment of infectious disease.
IPSCIO Record ID: 28615
During the first 18 months of the Agreement, neither the Licensor or Licensee may terminate the Channel Agreement other than in the event of a material breach. Following the first 18 months of the Agreement, the Licensor may also terminate the Channel Agreement if the Company fails to use diligent efforts to develop and commercialize Products or if the Licensee elects not to pursue the development of a Lantibiotics Program identified by the Licensor that is a Superior Therapy as defined in the Channel Agreement. Following the first 18 months of the Agreement, the Licensee may voluntarily terminate the Channel Agreement at any time upon 90 days written notice.
Upon termination of the Channel Agreement, the Licensee may continue to develop and commercialize any Product that, at the time of termination
is being commercialized by the Licensee;
has received regulatory approval;
is a subject of an application for regulatory approval that is pending before the applicable regulatory authority; or
is the subject of at least an ongoing Phase I, Phase A, Phase II or Phase III clinical trial, or an ongoing Phase I clinical trial in the Field.
IPSCIO Record ID: 209550
Licensor grants the non-exclusive, perpetual, transferable rights and licenses, with the right to sublicense, to use the Proprietary Information, Technical Information and Patented Technology for manufacture of Lysostaphin Preparations for use by Licensee in research, in the Licensed Products, and for sale to Licensor or its designee.
The proprietary information is Lysostaphin Production for E. coli production strain; Bacillus Sphericus production strain; and Manufacturing processes.
Lysostaphin is a Staphylococcus simulans metalloendopeptidase. It can function as an antimicrobial against Staphylococcus aureus.
The Technical information is all information other than proprietary information.
U.S. Patent No. 4,931,390 – Expression Of The Cloned Lysostaphin Gene
U.S. Patent No. 4,980,163 – Novel Bacteriocin Compositions For Use As Enhanced Broad Range Bactericides And Methods Of Preventing And Treating Microbial Infection
U.S. Patent No. 5,760,026 – Method For Treating Mastitis And Other Staphylococcal Infections
U.S. Patent No. 5,858,962 – Compositions For Treating Mastitis And Other Staphylococcal Infections
U.S. Patent No. 6,028,051 – Method For The Treatment Of Staphylococcal Disease
Serial No. 09/120,030 – A Method For The Treatment Of Staphylococcal Disease
Serial No. 09/263,776 – Compositions And Methods For Treatment of Stphylococcal Infection While Suppressing Formation of Antibiotic-Resistant Strains
Mastitis is inflammation of the breast or udder, usually associated with breastfeeding.
Staphylococcus is a genus of Gram-positive bacteria that can cause a wide variety of infections in humans and other animals through infection or the production of toxins. Staphylococcal toxins are a common cause of food poisoning, as they can be produced in improperly-stored food.
IPSCIO Record ID: 26258